Inclusion body myopathy associated with Paget's disease of the bone and frontotemporal dementia is attributed to mutations in the valosin-containing protein (VCP) gene, mapped to chromosomal region 9p13.3–12. Affected individuals exhibit scapular winging and die from progressive muscle weakness and cardiac and respiratory failure in their 40s to 50s. Mutations in the VCP gene have also been associated with amyotrophic lateral sclerosis in 10–15% of individuals with hereditary inclusion body myopathy and 2–3% of isolated familial amyotrophic lateral sclerosis. Currently, there are no effective treatments for VCP-related myopathy or dementia. To determine the effects of targeted excision of the most common R155H mutation in VCP disease, we generated the Cre-ER™-VCPR155H/+ tamoxifen-inducible model. We administered tamoxifen (0.12 mg/g body weight) or corn oil (vehicle) to the pregnant dams by oral gavage and monitored survival and muscle strength measurements of the pups until 18 months of age. We confirmed efficient removal of exons 4 and 5 and recombination of the mutant/floxed VCP copies by Q-PCR analyses. The activity and specificity of Cre recombinase was confirmed by immunostaining. Herein, we report that Cre-ER™-VCPR155H/+ mice demonstrated improved muscle strength and quadriceps fibers architecture, autophagy signaling pathway, reduced brain neuropathology, decreased apoptosis, and less severe Paget-like bone changes. The Cre-ER™-VCPR155H/+ mouse model provides proof of principle by demonstrating that removal of the mutated exons could be beneficial to patients with VCP-related neurodegenerative diseases, and serves as an excellent platform in understanding the underlying pathophysiological mechanism(s) in the hopes of a promising therapeutic approach.
Get full access to this article
View all access options for this article.
References
1.
KimonisVE, et al.Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med, 2000; 2:232–241.
2.
KovachMJ, et al.Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab, 2001; 74:458–475.
3.
WattsGD, et al.Clinical and genetic heterogeneity in chromosome 9p associated hereditary inclusion body myopathy: exclusion of GNE and three other candidate genes. Neuromuscul Disord, 2003; 13:559–567.
4.
WattsGD, et al.Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet, 2004; 36:377–381.
5.
KimonisVE, et al.Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A, 2008; 146:745–757.
6.
KimonisVE, et al.VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta, 2008; 1782:744–748.
7.
KimonisVE, WattsGD. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord, 2005; 19:S44–S47.
8.
KimonisV, et al.Inclusion body myopathy associated with paget disease of bone and/or frontotemporal dementia gene. Muscle Nerve, 2011. DOI: 10.1002/mus.23960.
9.
SchroderR, et al.Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann Neurol, 2005; 57:457–461.
10.
DjamshidianA, et al.A novel mutation in the VCP gene (G157R) in a German family with inclusion-body myopathy with Paget disease of bone and frontotemporal dementia. Muscle Nerve, 2009; 39:389–391.
11.
Guyant-MarechalL, et al.Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology, 2006; 67:644–651.
12.
HaubenbergerD, et al.Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology, 2005; 65:1304–1305.
13.
BersanoA, et al.Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. Neurobiol Aging, 2007; 30:752–758.
14.
ViassoloV, et al.Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling. Clin Genet, 2008; 74:54–60.
15.
MillerTD, et al.Inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD): clinical features including sphincter disturbance in a large pedigree. J Neurol Neurosurg Psychiatry, 2009; 80:583–584.
16.
KumarKR, et al.Two Australian families with inclusion-body myopathy, Paget's disease of bone and frontotemporal dementia: novel clinical and genetic findings. Neuromuscul Disord, 2010; 20:330–334.
17.
FanganielloRD, et al.A Brazilian family with IBMPFD caused by p.R93C mutation in the VCP gene and literature review for genotype-phenotype correlations. Exp Brain Res, 2011; 44:374–380.
18.
KimEJ, et al.Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family. Arch Neurol, 2011; 68:787–796.
19.
KomatsuJ, et al.Inclusion body myopathy with Paget disease of the bone and frontotemporal dementia associated with a novel G156S mutation in the VCP gene. Muscle Nerve, 2013. [Epub ahead of print]; DOI: 10.1002/mus.23960.
20.
WattsGD, et al.Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet, 2007; 72:420–426.
21.
SpinaS, et al.Frontotemporal dementia associated with a valosin-containing protein mutation: report of three families. FASEB J, 2008; 22:58.4.
22.
JohnsonJO, et al.Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron, 2010; 68:857–864.
23.
KimNC, et al.VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations. Neuron, 2013; 78:65–80.
24.
DeLaBarreB, et al.Central pore residues mediate the p97/VCP activity required for ERAD. Mol Cell, 2006; 22:451–462.
KomatsuM, et al.Autophagy and neurodegeneration. Autophagy, 2006; 2:315–317.
27.
LevineB, KroemerG. Autophagy in the pathogenesis of disease. Cell, 2008; 132:27–42.
28.
MalicdanMC, NishinoI. Autophagy in lysosomal myopathies. Brain Pathol, 2012; 22:82–88.
29.
TungYT, et al.Autophagy: a double-edged sword in Alzheimer's disease. J Biosci, 2012; 37:157–165.
30.
KemaladewiDU, et al.Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics, 2011; 4:36.
31.
PichavantC, et al.Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther, 2011; 19:830–840.
32.
ShiS, et al.Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS One, 2013; 8:e69096.
33.
BadadaniM, et al.VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One, 2010; 5:e13183.
34.
ZhangW, et al.Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery, 1996; 38:587–590; discussion 590–591.
35.
FurukawaS, et al.The impairment of metrial gland development in tamoxifen exposed rats. Exp Toxicol Pathol, 2012; 64:121–126.
36.
VerrouC, et al.Comparison of the tamoxifen regulated chimeric Cre recombinases MerCreMer and CreMer. Biol Chem, 1999; 380:1435–1438.
37.
NalbandianA, et al.A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse. Muscle Nerve, 2013; 47:260–270.
38.
VesaJ, et al.Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts. Neuromuscul Disord, 2009; 19:766–772.
39.
de MedinaP, et al.Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy, 2009; 5:1066–1067.
40.
KudohH, et al.A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system. Biochem Biophys Res Commun, 2005; 328:507–516.
41.
AokiY, et al.Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA, 2012; 109:13763–13768.
42.
MalerbaA, et al.Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of duchenne muscular dystrophy. Mol Ther Nucleic Acids, 2012; 1:e62.
43.
YangL, et al.Effective exon skipping and dystrophin restoration by 2′-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. PLoS One, 2013; 8:e61584.
44.
WuB, et al.Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA, 2008; 105:14814–14819.
